Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Ivonescimab on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Ivonescimab is a lung cancer medicine developed in China by Akeso, where it is sold as 依达方®. It is the first approved antibody that blocks two targets at once: PD-1, which helps the immune system attack the cancer, and VEGF, which tumours use to grow new blood vessels. It is given as a drip every three weeks, on its own or with chemotherapy, depending on the type of lung cancer.
China's National Medical Products Administration (NMPA) has approved it for three uses in non-small cell lung cancer (NSCLC):
It is a prescription cancer medicine and should only be used under a medical oncologist.
Cancer cells often hide from the immune system by switching off T cells through a "brake" called PD-1. At the same time, they release VEGF to build a blood supply. Ivonescimab is a single bispecific antibody that grips both. It releases the brake on the immune cells and starves the tumour of new blood vessels, so the two effects work together inside the tumour.
After EGFR tablets stop working (HARMONi-A): this phase 3 trial, published in JAMA in 2024, included 322 people in China whose EGFR-mutated lung cancer had grown after TKI treatment. Adding ivonescimab to pemetrexed and carboplatin chemotherapy pushed back the time before the cancer grew again from a median of 4.8 to 7.1 months (hazard ratio 0.46). Half of patients responded to treatment (50.6%), against about a third (35.4%) on chemotherapy alone.
First treatment for PD-L1 positive lung cancer (HARMONi-2): in 398 patients, ivonescimab alone was compared with a widely used PD-1 immunotherapy. The median time before the disease got worse was 11.1 months against 5.8 months (hazard ratio 0.51). In September 2026 Akeso reported that an interim survival analysis also met its goal; full survival figures had not yet been published.
Squamous lung cancer (HARMONi-6): in 532 patients, ivonescimab plus chemotherapy was compared with a different PD-1 immunotherapy plus chemotherapy. Median survival was 27.9 months against 23.7 months (hazard ratio 0.66), and the time before the disease got worse was 11.1 against 6.9 months.
In the HARMONi-A and HARMONi-2 trials the dose was:
The vial on the official pack is marked 100 mg in 10 mL. As an example, at 20 mg per kg a 60 kg patient would need 1,200 mg, or 12 vials, per dose. Your oncologist sets the exact plan and decides whether chemotherapy is needed.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Ivonescimab combines two kinds of side effects: immune-related ones, seen with PD-1 medicines, and blood-vessel related ones, seen with VEGF blockers. The figures below are from the HARMONi-A trial, where it was given with chemotherapy.
Overall: severe treatment-related side effects occurred in 61.5% of patients on ivonescimab plus chemotherapy and 49.1% on chemotherapy alone, and 5.6% stopped ivonescimab because of side effects (2.5% in the comparison group). When used on its own in HARMONi-2, severe treatment-related side effects were reported in 29% of patients. Safety in pregnancy, breastfeeding and children has not been established.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The injection can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval and is not sold in Indian pharmacies. In the United States, the FDA is reviewing an application for its use after EGFR tablets, with a decision date of 14 November 2026, but it is not yet approved there or in Europe.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For other EGFR-mutated lung cancer medicines we can help import, see our pages on Rybrevant and Lazcluze.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The vials are stored and shipped as directed on the pack, with temperature-controlled shipping to the treating hospital. Because the dose depends on body weight and is given every three weeks, we plan the number of vials cycle by cycle. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the treating hospital on a valid oncologist's prescription.
Large thoracic oncology departments here see lung cancer patients from across North India, and our New Delhi dispatch point keeps transit time short.
Vials can be delivered to the hospital day-care unit ahead of each three-weekly infusion.
Oncologists in Bangalore can request it for a named patient after reviewing EGFR, ALK and PD-L1 results, with a written quote before ordering.
A major referral centre for lung cancer in South India, used to handling imported biologic infusions.
We match each shipment to the patient's weight-based dose so the right number of vials arrives for every cycle.
Patients from Kolkata and the eastern states can receive supply at their treating hospital through the same documented route.
Families in Pune get stage-by-stage updates from prescription check to hospital delivery.
The treating oncologist can send the prescription, biopsy and molecular test reports to start the import.
Patients under care at hospitals in Vellore can have each cycle's vials sent directly to the hospital pharmacy.
Serves patients from Punjab, Haryana, Himachal Pradesh and Jammu, with delivery to the treating cancer centre.
We coordinate delivery to public and private cancer hospitals across Uttar Pradesh.
Patients across Kerala can receive their infusions at hospitals in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
